rhod immune globulin rhig medication used prevent rhd isoimmunization mothers rhd negative treat idiopathic thrombocytopenic purpura itp people rh often given following may also used rhdnegative people given rhdpositive given injection muscle single dose lasts made human blood common side effects include fever headache pain site injection red blood cell side effects include allergic reactions kidney problems small risk viral itp amount red blood cell breakdown may use safe rhod immune globulin made antibodies antigen rhod present red blood believed work blocking persons immune system recognizing rhod immune globulin came medical use following pioneering work john g gorman gorman shared laskerdebakey clinical medical research award pioneering work rhesus blood group rhig world health organizations list essential even normal pregnancies small number fetal blood cells enters maternal bloodstream fetomaternal hemorrhage mother rhd negative fetus rhd positive mothers immune system may develop immune response develops antibodies unfamiliar rhd antigens fetus process called rhd alloimmunization alloimmunization usually minimal effect first pregnancy second pregnancy preexisting maternal rhd igg antibodies cross placenta enough amounts damage fetal red blood cells condition called erythroblastosis fetalis fatal rhd status fetus determined genetic inheritance pregnancy mother rhd negative father rhd positive probability fetus rhd positive blood dependent whether father homozygous rhd ie rhd alleles present heterozygous ie one rhd allele present father homozygous fetus necessarily rhd positive father necessarily pass rhd positive allele father heterozygous chance fetus rhd positive randomly pass either rhd positive allele exposure fetal blood cells cause rhd alloimmunization happen normal pregnancy delivery miscarriage amniocentesis cordocentesis chorionic villus sampling external cephalic version women develop antid pregnancy weeks rhd negative mother rhig temporarily prevent sensitization maternal immune system rhd antigens μg antid able neutralize ml fetal widespread use rhig rh disease fetus newborn almost disappeared developed world risk rhd negative mother alloimmunized rhd positive fetus reduced approximately less appropriate administration countries without rh immune globulin rhig protocols many affected fetuses stillborn live births result neonatal death brain american college obstetricians gynecologists acog recommends rhd negative mothers regardless fetal blood type receive rhig weeks gestation shortly delivery case rhd positive rhd unknown given within days potential exposure rh positive blood baby may occur second third trimester miscarriage amniocentesis cordocentesis chorionic villus sampling external cephalic version trauma delivery amounts detailed next given intramuscular injection part modern routine antenatal care despite excellent results medication retains fda pregnancy category ccitation needed rhig recommended uk antenatal pathological events likely cause hemorrhage applicable pathologic events include accidents may induce fetomaternal hemorrhage motor vehicle accidents falls abdominal trauma following obstetricgynecologic procedures pregnancy time threatened spontaneouselective abortions regardless gestational age rhig also recommended normal delivery amounts detailed next insufficient evidence use rhod immune globulin spontaneous miscarriage needed cochrane review recommends local practices rh immune globulin composed igg antibodies therefore able cross placenta rare cases cause baby weakly positive direct antiglobulin test dat due sensitization fetal cells mothers received multiple doses rhig however treatment necessary clinical course widespread use rhig started postpartum administration delivery main source significant fetomaternal hemorrhage dnegative mother alloimmunized also receive appropriate dose rhig delivery dpositive infant older recommendations rh status infant known delivery testing cord infant dpositive mother postpartum blood sample screened fetomaternal hemorrhage order determine appropriate dosage rhig administered presence residual antid antepartum rhig administration indicate ongoing protection alloimmunization repeat administration rhig rosette test sensitive method detect fetomaternal hemorrhage cc qualitative quantitative test positive fetal dpositive cells present maternal sample indicating significantly large fetomaternal hemorrhage occurred rosette test may falsely positive mother positive weak phenotype falsely negative neonate weak mother positive weak phenotype rosette test used instead quantitative test test flow cytometry utilized rosette test negative dose micrograms rhig given sufficient prevent alloimmunization delivery rhig dose suppresses immune response cc whole fetal blood cc red blood cells fetomaternal hemorrhage excess cc occurred additional testing mandatory order determine appropriate dosage rhig prevent alloimmunization positive rosette test followed quantitative test test alternative approach flow cytometry see article test details volume fetomaternal hemorrhage calculated dosage rhig calculated volume fetal hemorrhage ml ex ml fetal hemorrhage ml round add vials rhigcitation needed postpartum rhig administered within hours delivery prophylaxis delayed likelihood alloimmunization prevented decreased however acog still recommends rhig administered partial protection still dtype newborn stillborn unknown determined rhig administered primary immune thrombocytopenia itp acquired immunemediated disorder characterized isolated thrombocytopenia defined peripheral blood platelet count less x absence obvious initiating andor underlying cause thrombocytopenia symptoms itp include abnormal bleeding bruising due reduction platelet rhod immune globulin intravenous human antid indicated use nonsplenectomized rhodpositive children chronic acute itp adults chronic itp children adults itp secondary hiv infection antid must administered via intravenous route used clinical situations requiring increase platelet count mechanism action antid fully understood however administration antid coated red blood cell complexes saturate fcγ receptors sites macrophages resulting preferential destruction red blood cells rbcs therefore sparing antibodycoated antid recommended firstline therapy itp along corticosteroids intravenous immune globulin winrho sdf antid manufactured distributed marketed cangene us black box warning winrho sdf due risk potentially fatal intravascular hemolysis used treatment lifethreatening anemia kidney failure disseminated intravascular coagulation dic occurred people treated winrho sdf itpcitation needed following females candidates rhig first rhod immune globulin treatment skymed introduced ortho clinical diagnostics subsidiary holding jskymed first administered may marianne cummins teaneck new zlb bioplasma part csl behring given approval sell rhophylac europe effectiveness demonstrated clinical trial rhophylac approved united conventional rhod immune globulin extracted human blood plasma excluding autoimmunity people rhod negative make antid antibody result limited pool people draw plasma contain desired igg special antid donation programs set account volunteers given injection containing antigen order make immune system start producing antibody alloimmunization boost amounts men women ability become pregnant may common way antid products manufactured form cohn cold ethanol fractionation process developed variations cohn method developed may completely clear aggregates immunoglobulins cause problems patients administered intravenously primary reason antids intramuscular use noncohn manufacturing variation chromaplus process approved us food drug administration fda used make rhod immune globulin may trigger allergic reaction steps taken plasmadonor screening process manufacturing process eliminate bacterial viral contamination although small residual risk may remain contamination small viruses also theoretical possibility transmission prion responsible disease unknown infectious continual attempts produce monoclonal antid igg formulation suitable replacing current polyclonal monoclonal antibody produced without requiring human donors associated supply disease risks would consistent batch india approved monoclonal formulation called rhoclone bharat serums vaccines made hybridoma cultures country also tested recombinant version rhoclone expressed cho roledumab rozrolimupab two formulations undergone clinical trials former monoclonal igg latter recombinant mixture rhig administered either intramuscular im intravenous iv injection depending preparation imonly preparation never administered iv due risk complement system activation multiple im doses given different sites different times within window multiple iv doses administered according instructions package insertcitation needed rhod immune globulin also spelled immune globulin letter digit zero widely attested rh blood group system rh nomenclature rhophylac manufactured csl limited rhogam micrhogam brand names kedrion biopharma brand names bayrhod gamulin rh hyprhod minidose minigamulin rh partobulin sdf baxter rhesonativ octapharma rhesugam nbi kamrhod im brand name kamada ltd united states distribution rights winrho sdf another brand name transferred baxter manufacturer cangene held baxter since sales winrho fell every year agreement baxter supposition baxter favoring sale product winrho according one analyst winrho always afterthought big company like